Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001079973-25-000599
Filing Date
2025-04-07
Accepted
2025-04-07 16:51:15
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5930
  Complete submission text file 0001079973-25-000599.txt   7711
Mailing Address 2401 4TH AVE. SUITE 1050 SEATTLE WA 98121
Business Address 2401 4TH AVE. SUITE 1050 SEATTLE WA 98121 206-838-0500
Aptevo Therapeutics Inc. (Subject) CIK: 0001671584 (see all company filings)

EIN.: 811567056 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-89584 | Film No.: 25818787
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 161A SHEDDEN ROAD ONE ARTILLERY COURT P.O. BOX 10085 GRAND CAYMAN E9 KY1-1001
Business Address 161A SHEDDEN ROAD ONE ARTILLERY COURT P.O. BOX 10085 GRAND CAYMAN E9 KY1-1001 646-688-5654
L1 Capital Global Opportunities Master Fund, Ltd. (Filed by) CIK: 0001702202 (see all company filings)

EIN.: 981241877 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G